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Abstract
HLA-restricted immune escape mutations that persist following HIV transmission could gradually spread through the
viral population, thereby compromising host antiviral immunity as the epidemic progresses. To assess the extent and
phenotypic impact of this phenomenon in an immunogenetically diverse population, we genotypically and
functionally compared linked HLA and HIV (Gag/Nef) sequences from 358 historic (1979–1989) and 382 modern
(2000–2011) specimens from four key cities in the North American epidemic (New York, Boston, San Francisco,
Vancouver). Inferred HIV phylogenies were star-like, with approximately two-fold greater mean pairwise distances in
modern versus historic sequences. The reconstructed epidemic ancestral (founder) HIV sequence was essentially
identical to the North American subtype B consensus. Consistent with gradual diversification of a ‘‘consensus-like’’
founder virus, the median ‘‘background’’ frequencies of individual HLA-associated polymorphisms in HIV (in
individuals lacking the restricting HLA[s]) were ,2-fold higher in modern versus historic HIV sequences, though these
remained notably low overall (e.g. i nG a g ,m e d i a n sw e r e3 . 7 %i nt h e2 0 0 0 sv e r s u s2 . 0 %i nt h e1 9 8 0 s ) .H I V
polymorphisms exhibiting the greatest relative spread were those restricted by protective HLAs. Despite these
increases, when HIV sequences were analyzed as a whole, their total average burden of polymorphisms that were
‘‘pre-adapted’’ to the average host HLA profile was only ,2% greater in modern versus historic eras. Furthermore,
HLA-associated polymorphisms identified in historic HIV sequences were consistent with those detectable today,
with none identified that could explain the few HIV codons where the inferred epidemic ancestor differed from the
modern consensus. Results are therefore consistent with slow HIV adaptation to HLA, but at a rate unlikely to yield
imminent negative implications for cellular immunity, at least in North America. Intriguingly, temporal changes in
protein activity of patient-derived Nef (though not Gag) sequences were observed, suggesting functional
implications of population-level HIV evolution on certain viral proteins.
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Introduction
Escape from Human Leukocyte Antigen (HLA) class I-restricted
CD8+ T-lymphocytes (CTL) in Human Immunodeficiency Virus
Type 1 (HIV) occurs along mutational pathways that are broadly
reproducible based on the HLA alleles expressed by the host [1–
4]. The opposite phenomenon (that is, reversion of escape
mutations to consensus upon HIV transmission to an individual
lacking the restricting HLA) is somewhat more variable. While
some escape mutations revert relatively rapidly following trans-
mission [5–7], others do so more slowly [8,9]. Yet others (perhaps
because they harbor no fitness costs, or such costs are rescued by
the presence of compensatory mutations) revert rarely or not at all
[10–13]. If escape mutations reverted rapidly and consistently,
their prevalence in HLA-mismatched persons would remain stably
low (or negligible) over time [9]. However, escape mutations
persisting upon transmission could gradually spread throughout
the population [10,12,14–16]. Analogous to the negative impact of
transmitted drug resistance mutations on treatment efficacy [17],
acquisition of ‘‘immune escaped’’ HIV by persons expressing the
relevant HLA allele could undermine the ability of their CTL to
control infection. As such, the spread of HIV strains harboring
escape mutations throughout the population could gradually
undermine host antiviral immune potential, and potentially
diminish the protective effects of certain HLA alleles, as the
epidemic progresses [11,12,18].
The extent to which immune escape mutations are accumulat-
ing in HIV sequences over time remains incompletely elucidated –
a knowledge gap attributable in part to the scarcity of historic data.
Nevertheless, some supportive data exist. It has been suggested
that CTL epitopes in European HIV sequences are being ‘‘lost’’
over time through mutational escape, in particular via selection by
HLA-B alleles, though this study was limited by the modest
number of sequences analyzed [19]. Higher HIV polymorphism
frequencies have been reported in modern compared to historic
South American HIV subtype B and F sequences, though this
study was limited by the lack of host HLA characterization [20].
The high (,75%) frequency of the B*51-associated HIV Reverse
Transcriptase (RT) I135X mutation in Japan, a population where
B*51 prevalence approaches 20%, is also consistent with escape
mutation accumulation [12], though the possibility that the
Japanese epidemic was founded by an HIV sequence containing
RT-I135X cannot be ruled out. That certain (though not all)
escape mutations are capable of spreading in HIV-infected
populations has also been demonstrated via mathematical
modeling [9]. However, conclusive assessment of the extent to
which escape mutants are accumulating in circulation ideally
requires large datasets of linked HLA/HIV genotypes from
historic and modern eras, combined with ancestral (founder)
sequence reconstruction of the studied epidemics.
The potential pathogenic implications of population-level HIV
evolution are also of interest. It has been hypothesized that
conflicting selection pressures imposed on HIV by HLA-diverse
host populations could lead to (relative) viral attenuation over
time, while consistent pressures imposed by populations with
limited HLA diversity could increase HIV virulence [21].
However, the complex tradeoffs between immune evasion benefits
versus fitness costs of escape, and the context-specific nature of
these factors with respect to the host genetic milieu, render this a
challenging question to address. A recent meta-analysis of HIV
clinical prognostic markers (plasma viral load and CD4+ T-cell
counts) in cohorts from North America, Europe and Australia
suggested that HIV could be increasing in virulence [22], but
other reports have been highly conflicting [23–30]. Alternatively,
pathogenic implications may be investigated, albeit incompletely
and indirectly, via assessment of HIV protein function and/or
replication capacity of patient-derived viral sequences – though
historic data remain scarce. Reductions in replication capacity of
recombinant HIV expressing gag-protease sequences from Japa-
nese patients, a population with relatively constrained HLA
diversity [12,31], have been reported since the 1990s [32], while
two earlier studies examining replicative fitness of recombinant
viruses expressing HIV RT sequences from historic and modern
European isolates yielded opposing results [23,33].
The goals of the present study are to assess the extent to which
HLA-associated polymorphisms are accumulating in HIV se-
quences over time in a large epidemic region comprising an
immunogenetically diverse population (North America), and to
investigate whether any genotypic changes have been accompa-
nied by functional implications for the virus. To do this, we
genotypically and functionally assessed HIV sequences, linked to
host HLA information, from 358 historic (1979–1989) and 382
modern (2000–2011) specimens from four key cities in the
epidemic (New York [34,35], Boston [36,37], San Francisco
[34,38,39] and Vancouver, Canada [40–42]). We performed
ancestral phylogenetic reconstructions to infer North America’s
most recent common ancestor (MRCA) HIV sequence, and we
defined HLA-associated polymorphisms based on independent
published sources [43]. We focused on Gag and Nef, as these are
immunogenic HIV proteins whose sequence variability is
substantially influenced by HLA [43] and whose function is
susceptible to immune-mediated attenuation [44–46].
Overall, we observed an HIV epidemic that is steadily
diversifying (in part due to HLA pressures), where background
frequencies of HLA-associated polymorphisms have, on average,
increased by a modest extent over the study period. Notably, HIV
polymorphisms selected by protective HLA alleles appear to have
increased to a greater relative (though not absolute) degree than
those restricted by non-protective alleles. Despite these increases,
average escape mutation background frequencies remain, in
absolute terms, low. As such, we contend that HIV adaptation
to host HLA is unlikely to yield imminent negative implications for
cellular antiviral immunity, at least in North America. Intriguing-
ly, changes in Nef (though not Gag) activity were observed over
the epidemic’s course, suggesting functional impacts of ongoing
HIV evolution on certain viral proteins.
Results
HLA and HIV diversity in historic and modern cohorts
A total of 358 historic HIV sequences spanning 1979–1989,
from observational cohorts of men who have sex with men (MSM)
established in four key cities in the North American epidemic (New
York [34,35], Boston [36,37], San Francisco [34,38,39] and
Vancouver [40–42]), were studied alongside 382 modern North
American HIV sequences spanning 2000–2011 from untreated
Host Adaptation of HIV-1 in North America
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class I sequence-based typing, aided where necessary by imputa-
tion using a published [47] and extensively validated [43]
machine-learning algorithm, was successful for 330 (of 358;
92.2%) historic and 381 (of 382; 99.7%) modern specimens. The
lower success rate for historic samples reflects the use of serum or
plasma as a genomic DNA source [48]. A limitation of serum-
based typing is the potential overrepresentation of homozygous
types due to amplification of only one allele of the pair [48];
indeed, this bias was noted (e.g.: HLA-B homozygosity was 9% in
the historic compared to 5% in the modern cohort, p=0.03).
Nevertheless, historic and modern cohorts exhibited comparable
HLA allele frequencies (Pearson’s R=0.97, p,0.0001,
and Figure S1), indicating that our analyses of the spread of
HLA-associated HIV polymorphisms are unlikely to be majorly
confounded by intercohort differences in the frequencies of their
restricting HLA alleles.
Plasma HIV RNA amplification and bulk sequencing of Gag
and/or Nef was successful for the above-mentioned 358
historic specimens (of an original total of 497 specimens
tested, 72.0% genotyping success rate), yielding 299 Gag and
335 Nef sequences for study. Success rates of historic Gag and/
or Nef genotyping, by site, were: New York 73 (of 94; 77.6%),
San Francisco 32 (of 75; 42.7%), Boston 242 (of 282; 85.8%)
and Vancouver 11 (of 46, 23.9%). Infection stage was unknown
for most historic specimens, though these included 67
individuals with known or suspected early infection, all from
New York. Gag and/or Nef sequencing was successful for 382
modern specimens in total: 358 (93.7%) for Gag and 337
(88.2%) for Nef, all from individuals with chronic infection. All
HIV sequences were subtype B.
Estimated maximum-likelihood HIV Gag and Nef phylogenies
exhibited star-like shapes typical of HIV sequences sampled from
a population [49] (Figure 1). Despite being a convenience
sample, historic sequences exhibited no gross segregation by early
(1979–1982; N=28), mid (1983–1985; N=122) and later (1986–
1989; N=208) eras. Moreover, unique historic North American
sequences in the Los Alamos National Laboratory (LANL) HIV
database (totaling 27 Gag and 56 Nef sequences spanning 1982–
1989) were interspersed throughout the phylogenies, as were
sampled modern LANL sequences spanning 2000-present
(Figure 1). Despite some clustering by city and the predomi-
nance of historic sequences in two lineages of a combined
phylogeny (Figure S2), the historic and modern cohort
consensus HIV sequences were consistent with one another as
well as the LANL North American and global (worldwide)
subtype B consensus sequences (Figure S3), with all differences
occurring at highly variable residues. Results thus support our
HIV sequences as not grossly unrepresentative of the North
American epidemic.
HIV sequence diversity within the modern cohort was substan-
tiallygreaterthanthat ofthehistoriccohort(Figure1).Groupedby
era,themean(6standarddeviation[SD])patristic(pairwise)genetic
distances in Gag were 0.02060.004 (1979–1982), 0.02760.009
(1983–1985), 0.03460.009 (1986–1989), and 0.07460.012 (2000+)
substitutions per nucleotide site, while those for Nef were
0.04360.010, (1979–1982), 0.05760.014 (1983–1985),
0.07260.015 (1986–1989), and 0.1260.025 (2000+) substitutions
per nucleotide site. Modern HIV cohort sequences (all sampled
during chronic infection) exhibited comparable mean pairwise
distances to modern acute-phase subtype B sequences not included
in the previous analysis (not shown), suggesting that infection stage
was not a major confounder of our diversity estimates by era. Taken
together, results support a diversifying North American epidemic
[50] where average intra-subtype Gag and Nef genetic distances
have increased approximately two-fold since the 1980s.
North American Gag and Nef MRCA sequences are
essentially identical to consensus
Before claiming that any highly prevalent HIV polymorphism
has arisen as a result of its spread through the population over
time, it is important to rule out its presence at the epidemic’s
genesis (i.e. founder effect [51]). We therefore estimated the
founder virus sequence of the North American epidemic by
reconstructing the most recent common ancestor (MRCA)
sequence at the root of the Gag and Nef phylogenies. To this
end, we performed $50,000 MRCA reconstructions per HIV
protein on random subsets of the historic sequence data using
BEAST (see methods and [52]), and computed a ‘‘grand
consensus’’ MRCA reconstruction per protein (Figure 2). Over-
all, reconstruction confidence exceeded 80% for all but one codon
in Gag (residue 67) and for all but 6 codons in Nef (residues 15, 21,
51, 152, 178 and 205), all of which are highly polymorphic sites
(,70% amino acid conservation) (Figure 2). The consensus of
Gag sequence reconstructions at the MRCA differed from the
LANL North American HIV subtype B consensus at only four
residues (A67S, R76K, K91R and E102D), while the consensus of
Nef MRCA reconstructions was identical to it (Figures 2 and
S3). Note the four ancestor/consensus differences in Gag merit
cautious interpretation, as codon 67 was reconstructed with ,80%
confidence and the remainder are sites with ,60% conservation at
the amino acid level. MRCA reconstructions undertaken using
random subsamples of both historic and modern Gag and Nef
sequences were consistent with those computed from historic
sequences only (not shown). Finally, the grand mean MRCA date
estimate from phylogenetic reconstructions inferred from random
subsamples of both historic and modern sequences was 1965
(range 1962–1967). The consistency of this date with published
estimates of a 1960s U.S. epidemic origin [53–55] provides
Author Summary
Upon HIV transmission, many – though not all – immune
escape mutations selected in the previous host will revert
to the consensus residue. The persistence of certain escape
mutations following transmission has led to concerns that
these could gradually accumulate in circulating HIV
sequences over time, thereby undermining host antiviral
immune potential as the epidemic progresses. As certain
immune-driven mutations reduce viral fitness, their spread
through the population could also have consequences for
the average replication capacity and/or protein function of
circulating HIV sequences. Here, we characterized HIV
sequences, linked to host immunogenetic information,
from patients enrolled in historic (1979–1989) and modern
(2000–2011) HIV cohorts from four key cities in the North
American epidemic. We reconstructed the epidemic’s
ancestral (founder) HIV sequence and assessed the
subsequent extent to which known HIV immune escape
mutations have spread in the population. Our data
support the gradual spread of many - though not all -
immune escape mutations in HIV sequences over time, but
to an extent that is unlikely to have major immediate
immunologic consequences for the North American
epidemic. Notably, in vitro assessments of ancestral and
patient-derived HIV sequences suggested functional im-
plications of ongoing HIV evolution for certain viral
proteins.
Host Adaptation of HIV-1 in North America
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American epidemic.
HIV diversification is attributable, at least in part, to HLA
selection pressures
A diversifying epidemic will, by definition, feature increasing
viral polymorphism frequencies. Thus, to give relevance to our
objective of measuring the spread of HLA-driven polymorphisms
in HIV sequences over time, it is important to first demonstrate
that HIV diversification is driven, at least in part, by HLA
pressures. If so, we reasoned that HIV codons known to be under
selection by HLA would, on average, have diversified to a greater
extent than those not under selection by HLA.
To investigate this, we first needed to independently define a
list of HIV sites that are known to be under selection by specific
HLA alleles. We defined these based on an independent
published study of .1800 treatment-naı ¨ve individuals with
chronic HIV subtype B infection from cohorts in Canada, the
USA and Australia [43], that had no overlap with the historic or
modern cohorts studied here. In that study, HLA-associated
polymorphisms in HIV were identified using phylogenetically-
corrected association testing approaches (see methods and [43]).
For the present analysis of HLA selection and HIV diversifica-
tion, an inclusive definition of ‘‘HIV sites under selection by
HLA’’ was warranted; therefore, we defined this as all Gag and
Nef codons associated with at least one HLA allele that met a
false-discovery rate threshold of ,20% (q-value ,0.2) in the
independent study (see methods and [43]). This totaled 95 (of
500) codons in Gag and 99 (of 206) codons in Nef.
We began with Gag, by aligning historic and modern amino
acid sequences to the HIV reference strain HXB2 and computing
changes in Shannon Entropy on a per-codon basis (1000
bootstraps). This revealed 69 (of 500; 14%) codons whose
entropies were significantly higher (p,0.001, q,0.01) in modern
versus historic sequences (Figures 3A, 3B). To minimize
circularity of arguments, we next excluded highly (.99%)
conserved codons from consideration, as these cannot diversify
to any great extent (and as such, are rarely identified as HLA-
associated [43]) – leaving 219 ‘‘variable’’ Gag codons for analysis.
Stratifying these sites by their HLA status indicated that, of the 95
Gag sites under selection by HLA [43], 45.2% exhibited
significantly higher entropy in modern versus historic sequences,
compared to 21.0% of the 124 sites not associated with HLA
(p=0.0002, Figure 3C). This indicates that HLA-associated viral
sites tend to be those that have diversified the most between
historic and modern-era HIV sequences.
While entropy approaches strictly investigate the end products
of diversification, dN/dS-based approaches provide a more direct
Figure 1. Diversity of North American Gag and Nef sequences from historic (1979–1989) and modern (2000+) eras. Unrooted
Maximum likelihood phylogenetic trees, drawn on the same distance scale, are shown for historic Gag (upper left), historic Nef (lower left), modern
Gag (upper right) and modern Nef (lower right). Phylogenies are star-like, with Nef exhibiting greater diversity than Gag, and modern trees exhibiting
greater diversity than historic ones. Cohort sequences are colored by sampling era: red (1979–1982), green (1983–1985), blue (1986–1989) and purple
(2000+); North American sequences retrieved from the Los Alamos (LANL) database are in grey. Included in each tree is the HIV subtype B reference
strain HXB2, shown in black and indicated with an arrow.
doi:10.1371/journal.pgen.1004295.g001
Host Adaptation of HIV-1 in North America
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As such, we identified sites under significant pervasive positive
(diversifying) selection in a maximum-likelihood phylogeny com-
prising historic and modern sequences using the fast unconstrained
Bayesian approximation for inferring selection algorithm [56]. As
expected, after excluding codons that were .99% conserved, sites
under pervasive positive selection were more likely to experience a
significant increase in entropy (p,1610
25, not shown) (indicating
that positive selection is driving some of this diversification), and
were more likely to be HLA-associated (suggesting that HLA
represents a major source of this selection pressure) (p=0.0022,
Figure 3D).
We repeated these analyses for Nef, revealing trends consistent
with those observed for Gag (Figure S4). Results thus suggest that
ongoing HIV diversification is attributable, at least in part, to HLA
pressures.
Assessing the spread of HLA-associated polymorphisms
in the population over time
We now turn to our major goal of assessing the spread of HLA-
associated polymorphisms in the population over time. If escape
mutations in HIV are reproducibly selected in individuals
expressing particular host HLA(s), but such mutations consistently
and rapidly reverted upon transmission, then we would expect
Figure 2. Reconstructed ancestral sequences at the root of the inferred Gag and Nef phylogenies, representing the estimated most
recent common ancestor (MRCA) of the North American epidemic. A minimum of $50,000 reconstructions of the ancestral sequence at the
root of the Gag and Nef phylogenies were performed, and the inferred MRCA was computed as the ‘‘grand consensus’’ of these replicate
reconstructions. For each codon, reconstruction confidence (computed as the frequency of each amino acid observed across all reconstructions) is
indicated on the y-axis on a scale from 0 (0%) to 1 (100%). Blue letters represent the highest-confidence residue at each position; green letters
represent lower-confidence residues. All amino acids observed at .0.01 (.1%) reconstruction frequency are shown. Yellow boxes highlight positions
where the highest-confidence (blue) inferred ancestral residue differs from the North American consensus B sequence (displayed in Figure S3).
doi:10.1371/journal.pgen.1004295.g002
Host Adaptation of HIV-1 in North America
PLOS Genetics | www.plosgenetics.org 5 April 2014 | Volume 10 | Issue 4 | e1004295Figure 3. Gag residues exhibiting significant diversification over time are biased towards known HLA-associated sites. Panel A:
Differences in Shannon entropy (Dentropy) between modern and historic sequences are shown for every Gag codon. Positive y-values indicate higher
entropy in modern vs. historic sequences at that codon; negative y-values indicate the opposite. Red bars indicate significant entropy differences
(defined as p,0.001, q,0.01); blue colors indicate differences that do not reach this significance threshold. Grey dots designate known HIV sites
under selection by HLA (as defined in [43]). Green dots designate sites that display significant evidence of pervasive positive selection (dN/dS.1;
posterior probability .0.9). Panel B: Same as panel A, but sorted by decreasing Dentropy rather than codon order. Panel C: Graphical depiction of a
262 contingency table stratifying variable (,99% conserved) Gag codons based on their status as HLA-associated (yes vs. no), and whether they
exhibited significant Dentropy between modern and historic datasets (p,0.001 [red] vs. not [blue]). Ns are indicated above each bar. Panel D:
Host Adaptation of HIV-1 in North America
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expressing the relevant HLA(s), and generally low among
individuals lacking them, at levels that remain stable over time.
But, if HLA-associated polymorphisms were to persist upon
transmission and gradually spread in the population, we would
expect polymorphism frequencies among HLA-matched individ-
uals to remain stably higher, but polymorphism frequencies
among individuals lacking the restricting HLA(s) to increase over
time. As such, we stratified our HLA-associated polymorphism
frequency comparisons between epidemic eras with respect to
persons expressing, versus not expressing, the relevant HLA(s).
As before, we defined HLA-associated polymorphisms accord-
ing to an independent source [43]. Because the present analysis
investigated individual viral polymorphisms (rather than just sites)
associated with HLA, a more specific definition was warranted.
As such, we investigated all HLA-associated ‘‘adapted’’ (escape
mutant) forms meeting a false-discovery rate threshold of ,5% in
the original study (see [43] and methods). This list comprised
specific HLA-associated polymorphisms occurring at 71 Gag and
96 Nef codons [43]. HLA-associated polymorphisms in HIV were
additionally stratified based on whether they represented
consensus or non-consensus viral residues. Though the vast
majority of HLA-associated polymorphisms represent non-con-
sensus residues, a minority represent cases where an HLA allele is
associated with preservation of the consensus residue at a given
site (e.g. HLA-B*07:02 is associated with preservation of
consensus G357 in Gag) [43]. We analyzed such cases separately
because, under conditions of star-like diversification of a
‘‘consensus-like’’ founder, the null expectation is for polymor-
phism (i.e. non-consensus) frequencies to increase, and consensus
frequencies to decrease, over time. Separating them also allows
more intuitive interpretation when polymorphism frequencies are
summarized as averages.
We began by investigating the frequencies of 70 non-consensus
HLA-associated polymorphisms, occurring at 60 codons in Gag,
between HLA-expressing and non-expressing persons in the
historic and modern cohorts (Figure 4). As expected, individual
polymorphism frequencies varied widely, but they were neverthe-
less enriched among individuals expressing the relevant HLA(s)
(Figure 4A) compared to individuals lacking them (Figure 4B). In
accordance with the null expectation, polymorphism frequencies
in persons harboring the relevant HLA(s) were consistent across
historic (median 18%, Interquartile Range [IQR] 4–54%) and
modern (median 23% [IQR 7–45%]) cohorts (p=0.8; Figure 4A).
For example, Gag-242N frequency was $70% among persons
expressing a B58 supertype allele, regardless of era. In persons
lacking the relevant HLA(s), we also observed numerous examples
of polymorphisms whose frequencies remained stable between
historic and modern eras (e.g. Gag-242N frequency remained
,1% in persons lacking a B58 supertype allele) (Figure 4B).
Overall though, the average frequencies of these polymorphisms in
persons lacking the relevant HLA(s) were modestly, yet statistically
significantly, higher in modern (median 3.7% [IQR 2–19%])
compared to historic (median 2.0% [IQR 0.7–10%]) sequences
(p=0.0002; Figure 4B), a result consistent with the spread of
many – though not all – HLA-driven polymorphisms in the
population. Results remained significant after adjusting for minor
inter-cohort differences in HLA frequencies (as these influence
rates of polymorphism transmission) (p=0.001, Wilcoxon one-
sample test, not shown).
Under conditions where HLA-associated polymorphisms are, on
average, slowly spreading through the population, we would expect
the statistical associations between HIV polymorphisms and their
restricting HLA(s) to concomitantly weaken. Indeed, this appeared
to be the case. The median odds ratios of association between HIV
Gag polymorphisms and their restricting HLA(s) were modestly
lower in modern (median OR 3.1 [IQR 1.7–7.1]) compared to
historic (median OR 3.8 [IQR 1.2–17.5]) cohorts (p=0.009,
Figure 4C).
Similar trends were observed for the 89 non-consensus HLA-
associated polymorphisms occurring at 77 codons in Nef. Among
persons expressing the relevant HLA(s), Nef polymorphism
frequencies remained consistently elevated in historic (median
14% [IQR 3–50%]) and modern (median 15% [IQR 3–41%])
cohorts (p=0.7; Figure 4D). In persons lacking the relevant
HLA(s), examples of polymorphisms whose frequencies remained
stable across historic and modern cohorts were noted (e.g. Nef-94E
frequency remained ,1% in persons lacking B*08, while Nef-
135F remained ,10% in persons lacking A*23:01 and A*24)
(Figure 4E). Overall though, the average frequencies of these
polymorphisms in persons lacking the relevant HLA(s) were
modestly higher in modern (median 3.4% [IQR 1–12%])
compared to historic (median 2.0% [IQR 0.6–11%]) sequences,
though this did not reach statistical significance (p=0.054)
(Figure 4E). Median odds ratios of association between Nef
polymorphisms and their restricting HLA(s) were also slightly
lower in modern (median 3.1 [IQR 1.7–7.1]) compared to historic
(median 3.8 [IQR 1.2–17.5]) cohorts, though not significantly so
(p=0.065, Figure 4F).
We also investigated HLA-associated polymorphisms occurring
at 11 Gag and 19 Nef codons where the association represented
the consensus residue [43]. As expected, we observed higher
frequencies of these consensus residues in individuals restricting
the relevant HLA(s) compared to individuals lacking them (Figure
S5). We also observed trends, though not statistically significant,
towards lower consensus frequencies at these sites in modern
versus historic sequences, regardless of HLA alleles expressed
(Figure S5).
Taken together, our results are consistent with a scenario in
which, on average, non-consensus HLA-associated polymorphisms
have increased in frequency in North American HIV sequences
over time. That said, the observed increases for Nef were not
statistically significant, and both proteins harbored numerous
examples of HLA-driven polymorphisms with stable background
prevalence (e.g. Gag-242N, Nef-94E, Nef-135F). Moreover,
although results for Gag attained statistical significance, average
polymorphism background frequencies remained notably low,
regardless of era. Our results thus indicate that not all HLA-driven
polymorphisms are accumulating in circulation. Rather, our
results suggest a diversity in accumulation rates, with the majority
of nonconsensus polymorphisms spreading slowly (and others not
at all) – and consensus residues decreasing in frequency overall.
These observations confirm slow polymorphism spread predicted
by mathematical models [9] and are consistent with an epidemic
that is gradually diversifying under selection pressures that include
HLA.
Graphical depiction of a 262 contingency table stratifying variable (,99% conserved) Gag codons based on their status as HLA-associated (yes vs.
no) and evidence that they are under significant pervasive positive selection (dN/dS.1; posterior probability .0.9 [green] vs. not [black]). Ns are
indicated above each bar.
doi:10.1371/journal.pgen.1004295.g003
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sequences are ‘‘pre-adapted’’ to host HLA
Our results suggest that, on average, HLA-associated polymor-
phisms are spreading in the population, albeit slowly. From an
immunological perspective, an increasing burden of escape
mutations in circulating HIV strains over time could yield a
reduction in the ability of individuals to control the virus via cellular
responsesastheepidemicprogresses.Wethusasked:ifanindividual
were to be randomly infected by an HIV sequence from the historic
or modern eras, to what extent would the latter contain a higher
burden of polymorphisms that are ‘‘pre-adapted’’ to their HLA? To
estimate this quantity, we compared each individual’s HLA profile
against all historicandmodernchronic-phaseHIV sequences inour
dataset, and calculated the percentage of HLA-associated sites in
each sequence exhibiting the adapted form specific to each person’s
total HLA profile. Comparison of the overall per-person averages
thus represents the expected extent to which a randomly sampled
HIV sequence would be pre-adapted to a given individual, had they
been infected by a sequence from that era. Focusing first on
non-consensus HLA-associated polymorphisms, our calculations for
Gag yielded a median ‘‘percentage HIV sites pre-adapted to one’s
HLA profile’’ of 14.9% [IQR 10.1–19.5%] for historic versus a
median of 17% [IQR 12.7–22.4%] for modern sequences, an
average increase of only ,2% (Figure S6). Inclusion of consensus
HLA-associated polymorphisms further minimized this gap (not
shown). For Nef, the median ‘‘percentage of adapted sites’’
remained consistent across eras (19.0% in historic versus 18.5% in
modern) (Figure S6); moreover, inclusion of consensus polymor-
phismsresultedinloweroverall percentagesinmoderncomparedto
historic sequences (not shown). Results therefore suggest that,
Figure 4. Differences in non-consensus escape mutant frequencies in persons expressing versus not expressing the restricting HLA
allele(s), by era. Panel A: Frequencies of 70 published non-consensus HLA-associated polymorphisms (defined in [43]), in historic (1979–1989) and
modern (2000+) HIV Gag sequences from individuals expressing the restricting HLA allele(s) are shown as linked pairs. A selection of well-known HLA-
associated polymorphisms are labeled with their codons and restricting allele(s). P-values for all figure panels are computed using the Wilcoxon
matched-pairs test. Panel B: Frequencies of these same 70 HLA-associated polymorphisms in historic and modern HIV Gag sequences from
individuals lacking the restricting HLA allele(s). Panel C: Odds Ratios of association between these 70 HLA-associated Gag polymorphisms and their
restricting HLA allele(s) in historic (1979–1989) and modern (2000+) cohorts. Panel D: Frequencies of 89 published nonconsensus HLA-associated
polymorphisms in historic and modern HIV Nef sequences from individuals expressing the restricting HLA allele(s). Panel E: Frequencies of these
same 89 HLA-associated polymorphisms in historic and modern HIV Nef sequences from individuals lacking the restricting HLA allele(s). Panel F:
Odds Ratios of association between these 89 HLA-associated Nef polymorphisms and their restricting HLA allele(s) in historic and modern cohorts.
doi:10.1371/journal.pgen.1004295.g004
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acquiring escape mutant viruses specific to their HLA allele profile
has increased only minimally for Gag, and not at all for Nef, since
the 1980s in North America.
Polymorphisms restricted by protective HLA alleles
appear to be accumulating to a greater relative (though
not absolute) extent
Broadly speaking, at any given point in time, the average
background frequencies of HLA-associated polymorphisms in
circulating HIV sequences will generally positively correlate with
the frequencies of their restricting HLA alleles in the population
[12]. This is because higher absolute numbers of persons expressing
the HLA will generally translate to higher absolute numbers of
polymorphisms selected and thus transmitted (though many factors,
including the wide-ranging probabilities of polymorphism selection
given their location and restricting HLA, the fact that multiple HLA
alleles select the same – or opposing – mutations at a given location,
the existence of ‘‘consensus’’ HLA-associations, and the timing of
polymorphism selection/reversion, will render this correlation less
than perfect). Nevertheless, such a positive trend is observed in both
the historic and modern cohorts, as expected (Figure S7).
However, we are specifically interested in investigating the extent
to which HLA-associated polymorphisms are spreading through the
population over time. We thus asked: are polymorphisms restricted
by certain HLA alleles increasing to a greater extent than others?
To do this, we analyzed all HLA allele groups for which a
minimum of three HLA-associated polymorphisms (regardless of
whether they were consensus or non-consensus) were studied (25
alleles total). For each HLA-associated polymorphism, we
computed its fold-increase in background frequency over time
(for example, a hypothetical polymorphism with a background
frequency of 1% in the historic cohort versus 2% in the modern
cohort would equate to a two-fold increase). For each HLA allele
we then calculated the median fold-increase in frequency of all
polymorphisms restricted by it. Overall, we observed no significant
correlation between the frequency of a restricting HLA allele and
the relative extent to which its polymorphisms spread throughout
the population between historic and modern cohorts (Spearman’s
R=20.35, p=0.09) (Figure 5A). Taken together with the results
in Figure S7, this indicates that, at any given point in time,
polymorphisms restricted by common HLA alleles will generally
be found at higher absolute frequencies in a population than those
restricted by rarer ones, but such polymorphisms do not appear to
be spreading in the population to a greater relative extent (i.e.
when expressed in terms of fold-change) over time.
Strong epidemiological links between host carriage of specific
HLA class I alleles and HIV disease progression have been
demonstrated in natural history studies (e.g.: [57]), with some alleles,
notably HLA-B*57 and HLA-B*27, consistently associated with
slower progression [57–59]. We therefore wished to investigate the
relationship between an HLA allele’s ‘‘protective’’ status (defined as
its published Hazard Ratio for progression to AIDS [57]) and its
median fold-increase in polymorphism background frequency
between historic and modern eras. Of interest, we observed a
significant inverse correlation between these two parameters
(Spearman’s R=20.52, p=0.0076) (Figure 5B), suggesting that
polymorphisms restricted by protective HLA alleles have, in relative
(fold-change) terms, spread to a greater extent in the population
than those restricted by non-protective HLA alleles.
It is nevertheless important to contextualize these results in
absolute terms. Of the six HLA-B*57-associated sites studied in
Gag, historic sequences harbored a median 0 [IQR 0–1] B*57-
associated polymorphisms at these sites, compared to 1 [IQR 0–2]
in modern Gag sequences. Of the six B*57-associated sites in Nef
(two of which represent ‘‘consensus’’ associations), both historic
and modern sequences harbored a median of 2 [IQR 1–3] B*57-
associated adapted polymorphisms. It thus remains unclear to
what extent these modest absolute increases may compromise the
protective effects of certain HLA alleles as the epidemic progresses.
HLA-associated polymorphisms identified via association
approaches are consistent between historic and modern
cohorts
We have thus far defined HLA-associated polymorphisms as
those identified in independent modern cohorts by statistical
Figure 5. Protective HLA alleles are associated with the greatest relative increases in HLA-associated polymorphism background
frequencies. Each dot illustrates a single HLA class I allele, colored red, blue and green, for HLA-A, -B, and -C alleles, respectively. Panel A: No
significant correlation is observed between the frequency of a given HLA allele in the population (y-axis) and the relative extent to which its
polymorphisms have spread over time (computed as the median fold-difference in background frequency of its associated polymorphisms in modern
compared to historic HIV sequences; x-axis). This suggests that the accumulation of HLA-associated polymorphisms in circulating sequences is not
simply driven by common HLA alleles. Panel B: A significant inverse correlation is observed between an HLA allele’s Hazard Ratio of progression to
AIDS ([57], y-axis) and the relative extent to which its polymorphisms have spread in the population over time (x-axis). This suggests that HLA-
associated polymorphisms whose background frequencies have increased to the greatest relative extent between historic and modern eras are those
restricted by protective HLA alleles.
doi:10.1371/journal.pgen.1004295.g005
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historic HLA-associated polymorphisms that are no longer
detectable in modern sequences due to their spread throughout
the population, we applied association testing approaches to our
historic dataset directly. Historic patients with known or
suspected early infection were excluded (as these could dilute
associations between HLA and HIV polymorphisms due to
insufficient within-host evolution), and a false-discovery rate (q-
value) cutoff of 0.05 was employed. We were especially interested
to see whether HIV codons whose inferred ancestral (founder)
amino acid differed from the North American consensus (there
were 4 in Gag) or were reconstructed with ,80% confidence (1
in Gag and 6 in Nef) could be explained by the existence of
historic HLA-associated polymorphisms at these sites. However,
no such evidence was observed (Figure 6A, 6B). Instead,
analysis revealed 16
HLA-associated polymorphisms occurring at 10 Gag codons and
28 HLA-associated polymorphisms occurring at 13 Nef codons
that, with the exception of an association between B*49:01 and
the consensus G at Gag codon 62, were wholly consistent with
published escape pathways [43] and/or were confirmed in the
present modern cohort (not shown). In summary, the strongest
HLA-associated polymorphisms in historic sequences are consis-
tent with those identifiable today.
Figure 6. HLA-associated polymorphisms, identified via statistical association, in historic HIV sequences. Panel A: Gag immune
escape map, indicating the locations, specific amino acid residues and HLA restrictions of HLA-associated polymorphisms identified at q#0.05 in our
historic cohort. The HIV consensus B amino acid sequence is used as a reference. Shaded vertical bars separate blocks of 10 amino acids. ‘‘Adapted’’
amino acids (those over-represented in the presence of the HLA allele) are red. ‘‘Nonadapted’’ amino acids (those under-represented in the presence
of the HLA allele) are blue. UPPERCASE letters distinguish polymorphisms that survive correction for HIV codon covariation (‘‘direct’’ associations),
while lowercase letters distinguish polymorphisms that do not survive correction for codon covariation (‘‘indirect’’ associations). The notation ‘‘_ST’’
following an HLA (e.g. B58_ST) identifies associations identified at the supertype level. The locations of optimally-defined, HLA-restricted CTL epitopes
straddling or adjacent to HLA-associated polymorphisms are indicated. The well-known A*02-SL9 epitope (SLYNTVATL) epitope is also shown; no
historic HLA-associated polymorphisms were identified therein at q,0.05. The single ‘‘novel’’ historic HLA-associated polymorphism (B*49:01-62G) is
indicated with a purple asterisk. A green filled circle denotes the single Gag residue (codon 67) where the ancestral founder sequence was
reconstructed with ,80% confidence. Orange filled circles denote the four Gag residues (67, 76, 91 and 102) where the inferred ancestral founder
sequence differs from the published North American subtype B consensus sequence. None of these sites harbor HLA associations. Panel B: Nef
historic immune escape map. Green filled circles denote the six Nef residues where the ancestral founder sequence was reconstructed with ,80%
confidence (15, 21, 51, 152, 178, 205); none harbor HLA associations.
doi:10.1371/journal.pgen.1004295.g006
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HIV sequences
HIV Gag and Nef are highly immunogenic HIV proteins whose
sequence variability is substantially influenced by HLA [43] and
whose function is susceptible to immune-mediated attenuation
[44–46]. As such, we investigated whether the gradual spread of
immune escape mutations in North American Gag and Nef
sequences may be accompanied by overall changes in the average
viral replication capacity and/or protein function of patient-
Figure 7. Replicative implications of Gag diversification during the North American Epidemic. Panel A: Unrooted Maximum-Likelihood
phylogenies, drawn on the same distance scale, depicting the inferred ancestor (single black dot), early-historic (red, 1979–1982), mid-historic (green,
1983–1985), late-historic (blue, 1986–1989) and modern (purple, 2000+) Gag clonal sequences from unique patients that were used to construct
recombinant NL4-3 viruses for functional assessment. Panel B: NL4-3 normalized replication capacities of recombinant viruses containing the Gag
sequence of the inferred ancestral sequence (Mean6S.E.M. of 3 replicate measurements) as well as patient-derived Gag clonal sequences (one per
patient, representing the mean of $2 replicate measurements). An RC of 1 indicates replication equal to that of NL4-3 while RC.1 and ,1 indicate
RC higher or lower than NL4-3 respectively. Although visually there appears a trend towards lower replication capacity among Gag clones from early
historic (1979–1982) era, there no significant differences in RC between any of the groups (Kruskal-Wallis test, p=0.6).
doi:10.1371/journal.pgen.1004295.g007
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recombinant HIV strain expressing the epidemic’s inferred Gag
ancestral sequence, and another expressing the published global
subtype B consensus (Figure S3) in an HIV NL4-3 subtype B
reference strain backbone. We also generated recombinant HIV
NL4-3 strains expressing a single representative clonal Gag
sequence from 108 (of 120 originally selected; 90.0% success rate)
historic and 58 (of 71 originally selected; 82% success rate) modern
specimens (Figure 7A). A clonal (rather than quasispecies [60])
approach was adopted for the patient-derived sequences, as
variations in viral stock diversity resulting from differential
integrity of historic versus modern specimens could bias replicative
measurements. We assayed the in vitro replication capacity of these
recombinant viruses using a published reporter T-cell assay [60–
63]. Replication capacities (RC) were normalized to that of
parental NL4-3, such that values .1 and ,1 indicate RC greater
or less than NL4-3, respectively.
The replication capacities of recombinant viruses encoding the
inferred ancestral and global subtype B consensus sequences were
comparable to those of parental NL4-3 (Figures 7B and S8).
Recombinant viruses expressing historic or modern Gag clonal
sequences displayed a broad range of growth phenotypes, with
median RCs approaching that of NL4-3 (Figure 7B). Although
there appeared to be a trend towards lower RC among Gag
recombinant viruses from early historic (1979–1982) patients, this
was not statistically significant (Kruskal-Wallis p=0.6). Further-
more, no correlation was observed between the replication
capacity of a given Gag clone and its genetic distance from the
Gag NL4-3 sequence (Spearman’s R=0.03, p=0.6, not shown),
arguing against confounding effects attributable to our use of a
historic lab-adapted sequence (NL4-3) as a viral backbone.
Similarly, we cloned the inferred ancestral, global subtype B
consensus and a single representative Nef sequence from N=102
historic and N=86 modern patients into a GFP-expression vector
(Figures 8A and S8). As modulation of Nef function over the
natural history of infection is supported by some [64,65] (though
not all [66]) studies, and a minority of historic Nef clones were
derived from persons with known or suspected early infection, we
indirectly assessed infection stage as a potential confounder by
including Nef sequences from 52 modern chronic and 34 early
infection patients not included in previous analyses (sampled a
median of 72 [IQR 48–92] days after infection) in our comparison
group. Following transient transfection into an immortalized T-
cell line stably expressing CD4 and HLA-A*02, we assessed the
ability of these Nef clones to downregulate these molecules from
the cell surface by flow cytometry [67,68] (Figure 8B). The Nef
sequence from HIV reference strain SF2 served as a positive
control (SF2 is commonly used as a control in Nef functional
studies, as it possesses robust CD4 and HLA class I downregu-
lation activities, e.g. [67]); thus, normalized Nef functions of .1
and ,1 indicate activity greater or less than SF2, respectively. Nef
protein expression was verified by Western blot (Figure S8); 15
poorly functional Nef clones whose expression could not be
detected were excluded (since in vitro cloning defects or other
artifacts could not be ruled out), leaving 93 historic and 80 modern
clones for analysis.
CD4 downregulation activity of ancestral Nef was comparable
to that of reference strain SF2 (Figure 8B), while that of global
subtype B consensus Nef was ,3% lower (not shown). Nef clones
from historic and modern patients were generally highly functional
for CD4 downregulation and exhibited relatively narrow dynamic
ranges. Nevertheless, historic patient-derived Nef sequences
exhibited significantly lower CD4 downregulation abilities com-
pared to modern sequences (Kruskal-Wallis p,0.0001), with the
early (1979–1982) Nef clones exhibiting the lowest function overall
(Figure 8B). Nef-mediated CD4 downregulation of modern Nef
clones from individuals in early and chronic infection were
comparable (p=0.9, Figure 8B and not shown), arguing against
infection stage as a major confounder of this result.
The ability of the ancestral Nef sequence to downregulate HLA-
A*02 was ,3.5% higher than reference strain SF2 (Figure 8C),
while that of global subtype B consensus Nef was equivalent to SF2
(not shown). Although Nef clones from both historic and modern
patients were in general highly functional, historic Nef sequences
exhibited significantly lower HLA downregulation abilities com-
pared to modern Nef sequences (Kruskal-Wallis p,0.0001), with
the early (1979–1982) Nef clones displaying the lowest function
overall (Figure 8C). HLA downregulation capacities of modern
early Nef sequences were on average 1% higher than those from
modern chronic Nef sequences (p=0.14, Figure 8C and not
shown), arguing against infection stage as a major confounder.
The significantly lower Nef-mediated CD4 and HLA downregu-
lation observed in historic versus modern sequences was robust to
inclusion/exclusion of the 15 clones whose Nef expression was not
detectable by Western Blot (not shown).
Taken together, the lack of significant functional differences
between ancestral, subtype B consensus, and median patient-
derived Gag clones from historic and modern eras argues against
major replicative consequences of HIV Gag diversification during
the North American epidemic. In contrast, our Nef results suggest
the introduction of a highly functional founder virus to North
America in the 1960s, followed by a subsequent decline in average
Nef-mediated CD4 and HLA downregulation functions of patient-
derived sequences in the 1980s, that were restored to original
(‘‘founder’’) levels by the 2000s. The mechanisms and potential
role for host pressures in this phenomenon require further
investigation.
Discussion
The present study examined linked host (HLA) and HIV (Gag/
Nef) datasets from historic (1979–1989) and modern (2000–2011)
eras in North America to estimate the extent to which HLA-driven
polymorphisms may be spreading throughout circulating HIV
sequences over time on this continent. Phylogenies inferred from
historic and modern samples of HIV Gag and Nef sequence
variation were star-like in shape, yielding a reconstructed ancestral
(epidemic founder) virus sequence that was essentially identical to
North American subtype B consensus. Mean pairwise distances
between modern HIV Gag and Nef sequences were approximately
two-fold greater than those between historic sequences, supporting
a diversifying epidemic. Notably, Gag and Nef codons exhibiting
the most significant entropy increases over time were enriched for
known HLA-associated sites, consistent with a key role of HLA in
driving HIV diversification [69,70].
Also consistent with an approximate two-fold increase in HIV
diversity since the mid-1980s in North America, the average
‘‘background’’ frequencies of HLA-associated polymorphisms (i.e.
in individuals lacking the restricting HLA) were roughly two-fold
higher in modern compared to historic sequences. These
differences reached statistical significance for Gag, though not
for Nef. As expected, in both historic and modern cohorts, a
general positive correlation was observed between the frequency of
an HLA allele and the background frequency of its associated
polymorphism in the general population. However, the polymor-
phisms that, over time, appeared to be spreading to the greatest
relative extent (in terms of fold-change) were not those restricted
by common HLA alleles (Figure 5A) but rather those restricted by
Host Adaptation of HIV-1 in North America
PLOS Genetics | www.plosgenetics.org 12 April 2014 | Volume 10 | Issue 4 | e1004295Figure 8. Functional implications of Nef diversification during the North American Epidemic. Panel A: Unrooted Maximum-Likelihood
phylogenies, drawn on the same distance scale, depicting the inferred ancestor (single black dot), early-historic (red, 1979–1982), mid-historic (green,
1983–1985), late-historic (blue, 1986–1989) and modern (purple: chronic-phase, orange: acute-phase, year 2000+) Nef clonal sequences from unique
patients cloned into a GFP-expression vector for functional assessment. Panel B: CD4 downregulation activities of the inferred ancestral Nef
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with our lack of identification of novel historic HLA-associated
polymorphisms restricted by common HLA alleles, indicates that
HIV is not simply adapting to the most frequent HLA alleles in a
given host population. Instead, our findings are consistent with
protective HLA alleles as those imposing the strongest evolution-
ary pressures on HIV, an observation that is consistent with
previous reports that protective HLA alleles are more likely to
induce strong selection at key conserved sites [43,71–73].
The spread of HLA-associated polymorphisms in circulation
could lead to a reduction in host antiviral immune potential over
time [12]. We thus wished to interpret our results in terms of the
imminence of this potential outcome. First and notably, the extent
of HLA-driven polymorphism accumulation in Nef did not reach
statistical significance. Second, though observations for Gag did
achieve significance, average polymorphism background frequen-
cies remained low in absolute terms (i.e. 2.0% in the 1980s versus
3.7% in the 2000s) – differences that, when expressed in terms of
the average estimated extent to which circulating HIV Gag
sequences are ‘‘pre-adapted’’ to an individual’s HLA profile,
translated into an overall increase of only ,2% between historic
and modern eras. Moreover, we observed numerous HLA-
associated polymorphisms whose prevalence remained stable in
the population (e.g. B58-supertype-associated Gag-242N, B*08-
associated Nef-94E, A*2301/A*24–associated Nef-135F), obser-
vations that are consistent with their rapid reversion upon
transmission [5,9,74] (though estimates of the reversion rate for
B*08-Nef-94E are somewhat conflicting [9,74]). That some -
though certainly not all - HLA-driven escape mutations are
capable of spreading through the population has been demon-
strated via mathematical modeling [9], indicating that the
reproducible selection of specific escape mutations in persons
harboring the relevant HLA does not always translate into rapid
evolution at the population level [9]. That certain HIV sites
simultaneously display strong signals for diversifying selection, yet
stable polymorphism prevalence, is also consistent with ‘‘toggling’’
between consensus and escape forms [75] as HIV disseminates in a
genetically diverse host population.
Although our study did not formally attempt to model the
dynamics of HLA-driven polymorphism spread in the North
American population, our observations suggest that this is
happening slowly. Very gradual polymorphism spread is also
consistent with mathematical models projecting that, even in the
case where an escape mutation never reverts, it could take
centuries for it to reach fixation following its initial appearance in
the population [9]. Moreover, it has been projected that any
reversion (however slow) would prevent a polymorphism from ever
becoming fixed [9]. Also consistent with slow spread is the near-
identity of the reconstructed epidemic MRCA (founder) HIV
sequence to the North American consensus - which suggests that,
between the North American epidemic’s genesis and the present
day, no polymorphism, HLA-driven or otherwise, has spread to an
extent where it now outcompetes that of the original founder
residue. Our lack of identification of novel historic HLA-associated
polymorphisms at the seven Gag/Nef codons where the inferred
ancestor was reconstructed with ,80% confidence and the four
(highly variable) Gag codons where it differed from the modern
consensus also argues against the spread of any historic HIV
escape mutation in North America to the point where it now
defines consensus. Note however that some caution is merited
when interpreting the estimated founder viral sequence, since
rapid selective sweeps occurring between the epidemic’s founda-
tion [54,55] and the earliest 1979 sampling date would not have
been detected and therefore cannot be ruled out. Acknowledging
these caveats, the near-identity between the estimated North
American founder virus and modern consensus additionally
suggests that statistical associations between particular HLA alleles
and the HIV consensus residue at a given site (e.g. B*07:02 with
Gag-G357) have not arisen as a result of their selection and
subsequent spread in the population to the point where they define
the consensus [10]. Rather, these residues were most likely present
at the epidemic’s foundation - and, if anything, are gradually
decreasing in frequency as HIV continues to diversify. We propose
that such ‘‘consensus HLA associations’’ represent cases where the
founder virus happened to be adapted to certain HLAs (perhaps
because the original founder or earlier hosts expressed them), and
that these HLAs continue to exert purifying selection on these sites
over time.
Despite inferred overall slow rates of accumulation, the
observation that polymorphisms restricted by protective alleles
appear to be spreading to a greater (relative) extent than others is
potentially important. Indeed, the stabilization of certain protec-
tive allele-associated escape mutations by secondary (compensato-
ry) substitutions has been documented: the S173A mutation
(which allows the B*27-associated Gag-R264K mutation to persist
upon transmission in an HIV subtype B context [11,13]) and the
S165N mutation (which stabilizes B*57-associated mutations
within the p24
Gag KF11 epitope in a subtype C context [8]), are
examples.
Despite this, we urge caution in extrapolating that the protective
effects of HLA alleles will diminish rapidly in North America.
Again, it is important to consider that absolute polymorphism
background frequencies remain low: modern Gag and Nef
sequences together harbor, on average, only one additional
B*57-associated polymorphism compared to historic sequences.
Similarly, despite polymorphism spread, a B*27-expressing
individual still has a .90% chance of acquiring HIV with the
immunologically susceptible consensus R at critical Gag codon
264. Besides, the protective effects of most such alleles (including,
to a certain extent, B*27 [76]) are attributable to consistent and
strong CTL responses against multiple HIV epitopes [43,77,78]. It
is also important to consider that protective HLA-restricted CTL
retain activity against polymorphic variants in many cases [79,80],
and de novo [81] or cross-reactive [82] CTL responses to in vivo
escape variants can, and do, arise. Further integrated evolutionary
and molecular studies are therefore required to assess the potential
immunologic impact of polymorphism spread on HIV control by
protective HLA alleles.
Our study also investigated whether HIV evolution in North
America has been accompanied by changes in viral replication
capacity or protein function. Consistent with previous in vitro
assessments of HIV sequences reconstructed using Center-of-Tree
sequence (mean6S.E.M. of 8 replicate measurements) and patient-derived Nef clones from various eras (one per patient, representing the mean of
triplicate measurements). CD4 downregulation values are normalized to that of HIV subtype B control Nef strain SF2, such that a value of 1 indicates
CD4 downregulation activity equal to that of SF2 while values.1 and ,1 indicate activities higher or lower than SF2 respectively. Modern Nefs
exhibited significantly higher CD4 downregulation activity compared to historic Nefs (Kruskal-Wallis p,0.0001). Panel C: SF2-normalized HLA class I
downregulation activities of inferred ancestral (mean6S.E.M. of 8 replicate measurements) and patient-derived Nef sequences (one per patient, mean
of triplicate measurements). Modern Nefs exhibited significantly higher HLA downregulation activity compared to historic Nefs (Kruskal-Wallis
p,0.0001).
doi:10.1371/journal.pgen.1004295.g008
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were highly functional. Despite substantial increases in Gag
diversity over time, the average replication capacities of recom-
binant NL4-3 viruses expressing patient-derived clonal Gag
sequences from historic and modern eras were comparable to
that of NL4-3 expressing the inferred Gag ancestral sequence,
arguing against major replicative consequences of HIV Gag
diversification during the North American epidemic. These results
contrast with reductions in replication capacity of recombinant
viruses expressing patient-derived Gag-protease sequences from
Japanese patients from the mid-1990s to present [32], a difference
possibly due to the greater homogeneity of HLA alleles in Japanese
compared to North American populations, that may exert
consistent selection pressures driving the selection of fitness-
reducing mutations.
In contrast, the average Nef-mediated CD4 and HLA
downregulation activities of historic patient-derived sequences
were modestly yet significantly lower than modern ones. This is
intriguing since the inferred Nef ancestral sequence displayed high
function. We therefore speculate that, following the introduction of
a functional ancestral Nef sequence into North America, initial
HIV adaptation to this new population led to decreases in Nef
function that were subsequently rescued upon continued Nef
diversification. The higher Nef-mediated HLA class I downreg-
ulation function of modern compared to historic sequences,
combined with the observation of modest HLA-driven polymor-
phism spread through the population during this same period,
raises the interesting possibility that, compared to viruses
circulating in the 1980s, modern North American HIV sequences
may exhibit greater immune evasion potential via enhanced HLA
class I downregulation [84] function. However, further studies will
be required to elucidate the underlying mechanisms and
pathogenic implications of these observations.
An anticipated criticism is our definition of HLA-associated
polymorphisms by statistical association studies of modern cohorts
[43]. This approach could underestimate the average extent of
polymorphism spread over time, for two reasons. First, such lists
could exclude historic escape mutations that are no longer
detectable in modern cohorts due to polymorphism spread. To
address this we applied statistical association approaches to
identify HLA-associated polymorphisms detectable at the popula-
tion level in the historic cohort. However, all identified polymor-
phisms save one were consistent with known HLA-associated
escape pathways, indicating that the strongest mutations detect-
able historically remain readily detectable today. A second
limitation is that association testing approaches, even those that
incorporate phylogenetic correction (as ours do), systematically
favor the identification of HLA-associated mutations that escape
and revert rapidly [85], which by definition would not be expected
to spread quickly in a population [9]. However, this limitation is
somewhat offset by the substantial size (N.1800) of the cohort
used to define HLA associations. Mathematical models indicate
that at such sample sizes, with phylogenetic correction, significant
associations can be detected between HLA alleles and polymor-
phisms even if these escape and/or revert on a timescale of
decades [85]. Moreover we have previously demonstrated that
cohorts of this size are powered to detect very rare HLA-associated
polymorphisms, as well as those that are nearly universally
observed in the population [43].
This study possesses additional limitations, many inherent to
convenience sampling and technical challenges of working with
historic samples. Although our sequences date back to 1979, the
lack of data from the critical period between HIV’s introduction
into North America and the late 1970s is a major limitation of this
and all other studies undertaken to date. Nevertheless, our historic
HIV sequence dataset is 10-fold (Gag) and 7-fold (Nef) larger than
existing data from this era and region, and includes the oldest
North American sequences ever published. Another limitation is
that specimens were obtained from only four sites in North
America, and all historic specimens were derived from observa-
tional studies of individuals from a single risk group (MSM)
[34,36–42]. As such, our HIV diversity estimates, particularly for
the historic era, may represent underestimates. Nevertheless, the
dispersion of published North American HIV sequences through-
out all phylogenies, the consistency of historic and modern
consensus sequences, and our estimated epidemic founder dates
that are compatible with published estimates [53–55] suggest that
our sequences are not grossly unrepresentative of the North
American epidemic. Concerns regarding our ability to faithfully
amplify the original quasispecies diversity from historic specimens
by PCR led us to adopt a single representative clone (rather than
bulk) approach for our functional assessments of Gag and Nef in
order to minimize in vitro bias associated with differences in the
diversity of viral stocks. The presence of individuals with known or
presumed early infection in our historic cohort and the general
lack of clinical staging information are also limitations. To reduce
confounding, early sequences were excluded from relevant
analyses (e.g. identification of HLA-associated polymorphisms in
the historic cohort and calculation of Odds Ratios of association
between HLA and polymorphisms), while other analyses verified
the appropriateness of pooling data by comparing early and
chronic sequences directly to rule out differences between them
(e.g. Nef functional assessments). The absence of pVL and CD4
information on historic patients also precluded the investigation of
trends in disease markers over time.
On the other hand, our development of a sensitive HLA
sequence-based typing assay capable of utilizing genomic DNA
extracted from plasma/serum [48] allowed us to perform HLA
typing of historic specimens, yielding, for the first time, the ability
to directly investigate HLA-associated selection pressures over the
course of an epidemic. A known limitation of serum-based HLA
typing is the overrepresentation of homozygous types due to
amplification bias [48], an effect that was noted in our historic
dataset. Though this could lead us to overestimate the historic
background frequencies of HLA-associated polymorphisms by
erroneously including individuals expressing the relevant HLA
into our calculations, the low average background frequencies of
HLA-associated polymorphisms in modern sequences indicate that
any overestimations would not substantially impact our overall
conclusions. A notable strength is the lack of overlap between
study cohorts and those from which the reference list of HLA-
associated polymorphisms was derived [43], thus ensuring
independence of source and query data.
In conclusion, HLA-associated polymorphisms are, on average,
slowly spreading throughout North American HIV sequences as
the epidemic continues to diversify. This slow adaptation to host
cellular immune responses parallels the observed drift of HIV
towards a more neutralization-resistant phenotype as a result of
population-level viral adaptation to humoral immune pressures
[86,87]. However, the absolute frequencies of these polymor-
phisms in circulation remain on average low on this continent, as
do the estimated risks of acquiring HIV ‘‘pre-adapted’’ to one’s
HLA profile. As such, our results are unlikely to translate into
major imminent consequences to CTL-mediated control of HIV,
at least in the North American region.
That said, we acknowledge that even modest changes can have
biological implications. Indeed, one could contend that modest
increases in the frequency of ‘‘pre-adapted’’ HIV strains are not
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time [22]. Furthermore, it is important to emphasize that the
potential rates, and thus immunologic implications, of HLA-
associated polymorphism spread may be substantially greater in
populations where HLA diversity is far lower and/or HIV
prevalence far higher than North America. Rates and implications
of polymorphism spread may also be more profound in
populations where transmission tends to occur later in infection,
thereby increasing the probability of transmitted escape mutations
(though mathematical models have suggested that realistic
differential transmission rates between acute and chronic infection
would impact population escape mutation prevalence only
minimally [9]). As such, we recommend that similar analyses of
virus-host adaptation be undertaken to assess the rate of
accumulation of immune-driven polymorphisms, and its patho-
genic implications, in other epidemic regions where historic
specimens are available. In conclusion, though our results remain
somewhat open to interpretation, we suggest that they be
considered in light of the major advances in HIV treatment and
prevention [88–92] that have occurred during the timecourse of
the present study. Combined with current efforts in prevention
and cure research [93–95], these advances give us firm hope that
the end of HIV/AIDS will precede the virus’ ability to fully
subvert host cellular immunity through population-level adapta-
tion.
Methods
Ethics statement
Research subjects, all adults, were enrolled under REB-
approved protocols and provided written informed consent to
participate in the original studies for which specimens were
collected. Ethical approval to conduct this study was obtained
from the Institutional Review Boards at Providence Health Care/
University of British Columbia and Simon Fraser University.
Historic and modern cohorts
A total of 497 historic plasma/serum specimens from unique
patients enrolled in observational studies of men who have sex
with men (MSM) at four North American sites between 1979–
1989, were obtained for study. Of these, 94 and 75 were from the
New York Blood Center (NYBC; 1979–1989) and the San
Francisco Department of Public Health (SFDPH; 1979–1984),
respectively, and represented participants of hepatitis B observa-
tional studies whose archived sera were retrospectively tested for
HIV [34,38,39]. A further 282 and 46 were obtained from the
Fenway Community Health Clinic in Boston (Fenway; 1985–
1989) [36,37] and the Vancouver Lymphadenopathy-AIDS Study
in Vancouver, Canada (VLAS; 1984–1987) [40–42]. With the
exception of 67 NYBC patients whose dates of HIV infection were
estimated to be within 6 months prior to specimen collection, all
other patients were known or presumed to be in chronic infection.
Specimen integrity varied by cohort. Whereas sera from NYBC,
SFDPH and Fenway were stored at 270uC since collection, VLAS
specimens had been stored at 220uC and bore evidence of freeze-
thaw cycles. No clinical information (i.e. plasma viral load, CD4)
was available for historic specimens; furthermore, sociodemo-
graphic and other identifying information were not sought. Our
modern comparison cohort comprised 382 individuals for whom
HIV Gag and/or Nef sequences were available: 26 were recruited
through the Aaron Diamond AIDS Research Center in New
York, 91 from Massachusetts General Hospital in Boston and 265
from various cohort studies based at the BC Centre for Excellence
in HIV/AIDS in Vancouver, Canada. The modern cohort
comprised MSM, injection drug users and individuals with
unknown HIV risk group.
Viral and host genotyping
HIV RNA was extracted from plasma or serum using standard
methods. Gag and Nef regions were amplified by nested RT-PCR
using sequence-specific primers and amplicons were bidirectionally
sequenced on a 3130xl and/or 3730xl automated DNA sequencer
(Applied Biosystems). Data were analyzed using Sequencher v5.0
(Genecodes) or RECall [96] with nucleotide mixtures called if the
height of the secondary peak exceeded 25% of the height of the
dominant peak (Sequencher) or 20% of the dominant peak area
(RECall). All HIV sequences were confirmed as subtype B using the
recombinant identification program (RIP; http://www.hiv.lanl.
gov/content/sequence/RIP/RIP.html). HXB2-alignments were
performed using an in-house tool based on the HyPhy platform
[97]. Phylogenetic trees were constructed using maximum-likeli-
hood approaches[98] andvisualized usingFigTree(http://tree.bio.
ed.ac.uk/software/figtree/). Patristic (pairwise) genetic distances
were computed using PATRISTIC [99]. Intercohort comparisons
of Shannon entropy scores (featuring 1000 randomizations with
replacement) were performed using Entropy-two (http://www.hiv.
lanl.gov/content/sequence/ENTROPY/entropy.html). Detection
of HIV Gag and Nef codons exhibiting significant evidence of
pervasive positiveselection(definedashavinga posteriorprobability
$0.9 that the site-specific nonsynonymous rate exceeds its
synonymous rate) in the combined historic/modern datasets was
performed using the fast unconstrained Bayesian approximation for
inferring selection algorithm [56], implemented in Datamonkey
[100,101].
Consensus sequences were calculated by plurality rule. North
American Gag and Nef HIV subtype B consensus sequences were
computed from all available Gag and Nef sequences from unique
patients annotated with Canada (CA) or United States (US)
country labels in the Los Alamos HIV sequence database
(N=1624 and N=1141 Gag and Nef amino acids sequences,
respectively, spanning 1983–2011, accessed June 25, 2013).
Historic plasma HIV RNA Gag and Nef sequences, annotated
with year and country of collection, have been deposited in
GenBank (Accession numbers KF701643–KF701941 for Gag and
KF701942–KF702276 for Nef).
HLA class I typing was performed using an in-house sequence-
based typing protocol capable of using plasma or serum as a
source of genomic DNA [48] and types were assigned using an in-
house algorithm. Where necessary, data were imputed to high
resolution using a machine learning algorithm trained on a dataset
of complete high resolution HLA-A, B and C types from .13,000
individuals with known ethnicity ([47]; http://research.microsoft.
com/en-us/projects/bio/mbt.aspx#HLA-Completion) and as-
signed the highest-probability allele combination. HLA types
could not be imputed when data were missing from more than one
locus.
Ancestral reconstructions & DNA synthesis
Gag and Nef sequences were annotated with sample dates.
Putative recombinants were identified using SCUEAL [102] and
removed. The most recent common ancestor (MRCA) sequences
of Gag and Nef were estimated using Bayesian evolutionary
analysis by sampling trees (BEAST) [52] via 6 (Gag) or 5 (Nef)
replicate chains, each analyzing a different set of 200 sequences
selected at random from the dataset, and yielding 10,000 ancestral
reconstructions per chain, as follows. Trees were sampled at
random from the posterior distribution of trees given an
exponential relaxed molecular clock [103], a Bayesian skyline
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substitution model determined by an Akaike information criterion-
based model selection procedure in HyPhy [97]. Sampling was
run for 2610
8 steps, with the first half discarded as burn-in and the
remainder thinned to 100 trees sampled at intervals of 10
6 steps in
the chain. Convergence of replicate chains was assessed using the
Tracer application in the BEAST software package. For each tree,
100 ancestral sequence reconstructions were sampled at random
from the posterior distribution defined at the root under a Muse-
Gaut codon substitution model in HyPhy. The inferred ancestral
sequence was taken as the consensus of these 60,000 (Gag) and
50,000 (Nef) reconstructions (10,000 each per chain for 6 [Gag]
and 5 [Nef] chains). Timing of each ancestral reconstruction
(tMRCA) was estimated in BEAST by computing the mean
estimate for each replicate chain and then computing a grand
mean. The ‘‘consensus ancestor’’ Gag and Nef nucleotide
sequences were commercially synthesized (Invitrogen LifeTech)
for use in functional analyses.
Definition and identification of HLA-associated
polymorphisms
The reference list of HLA-associated polymorphisms in modern
HIV subtype B sequences was defined in an independent
multicenter cohort of .1800 chronically subtype-B infected
individuals from Canada, the USA and Australia recruited in
the 1990s and 2000s, that did not overlap with historic and
modern cohorts analyzed herein, using phylogenetically-informed
methods [43]. The same methods [43] were used to identify HLA-
associated polymorphisms in the historic dataset, as follows.
Briefly, maximum likelihood phylogenetic trees were constructed
using Gag and Nef sequences, and a model of conditional
adaptation was inferred for each observed amino acid at each
codon. Here, the amino acid is assumed to evolve indepen-
dently along the phylogeny, until it reaches the tree tips
(representing the present host). In each host, selection via
HLA-mediated pressures and HIV amino acid covariation is
directly modeled using a weighted logistic regression, in which
the individual’s HLA repertoire and covarying amino acids are
used as predictors and the bias is determined by the possible
transmitted sequences as inferred by the phylogeny [104]. To
identify which factors (HLA and/or HIV covariation) contrib-
ute to the selection pressure, a forward selection procedure is
employed where the most significant association is iteratively
added to the model, with p-values computed using the
likelihood ratio test. Statistical significance is reported using
q-values [105], the p-value analogue of the false discovery rate
(FDR). Q-values denote the expected proportion of false
positives among results deemed significant at a given p-value
threshold; for example, at q#0.05, we expect 5% of identified
associations to be false positives. HLA-associated polymor-
phisms are grouped into two categories: (1) amino acids
significantly enriched in the presence of the HLA allele in
question (‘‘adapted’’ forms), and (2) amino acids significantly
enriched in the absence of the HLA allele in question
(‘‘nonadapted’’ forms).
Generation of recombinant viruses expressing clonal Gag
sequences from patients
Second round Gag amplicons were selected from 120
historic and 71 modern patients with known or presumed
chronic infection and cloned into the pCR2.1-TOPO TA
vector (Life Technologies, Burlington, ON, Canada). A single
representative clone harboring an intact Gag reading frame
that closely resembled the patient’s bulk plasma HIV RNA was
selected for virus generation [60,61]. Gag was amplified by
PCR from each clone using 100 bp-long primers matching the
NL4-3 sequence upstream and downstream of Gag, designed
to facilitate homologous recombination of the amplicon with
the pNL4-3Dgag backbone. The plasmid pNL4-3Dgag was
developed by inserting unique BstEII restriction sites at the 59
and 39 ends of gag using the QuikChange XL kit (Stratagene),
followed by deletion of the intervening region via BstEII
digestion (New England Biolabs), gel-purification, and re-
ligation (T4 DNA ligase; New England Biolabs). PNL4-3Dgag
was maintained in Stbl3 E. coli cells (Invitrogen). To generate
recombinant viruses, 10 mg of BstEII-linearized pNL4-3Dgag
plus 50 mlo f2
nd round Gag amplicon (,5 mg) were mixed with
2.5610
6 cells of a GFP-reporter T-cell line (CEM-derived
GXR25 cells [106]) in 125 ml of Mega-Cell medium (Sigma),
and transfected by electroporation in 96-well plates (exponen-
tial protocol: 250 Volts, 2000 mF; 25 millisecond pulse
duration; BioRad MxCell_Pro). Following transfection, cells
were rested for 15 min at room temperature, transferred to
25 cm
2 flasks containing 1 million GXR cells resuspended in
5m Lo fR 2 0 + medium (RPMI 1640 containing 20% FCS,
2 mM L-glutamine, 100 units/mL penicillin, and 100 mg/mL
streptomycin), and fed with 5 mL R20+ medium on day 5 and
with replacement thereafter. Tat-driven GFP expression,
indicating productive HIV infection of GXR cells, was
monitored by flow cytometry (Guava 8HT, Millipore) starting
on day 12 [60,61]. Once GFP+ expression exceeded 15%
among viable cells, supernatants containing recombinant
viruses were harvested and aliquots stored at 280uC. Patient
origin of all recombinant viruses was confirmed via sequencing
of the Gag region.
Assessment of Gag recombinant viral replication capacity
Viral titers and replication capacity (RC) assays were performed
using GXR25 GFP-reporter T-cells, as described [60,61]. RC
assays were initiated at MOI=0.003, and included one negative
control (uninfected cells only) and one positive control (NL4-3 Gag
re-introduced into the NL4-3Dgag backbone using identical
methods) per 24-well plate. For each virus, the natural log slope
of the percentage (%) of GFP+ cells was calculated during the
exponential phase of viral spread (days 3–6). This value was
divided by the mean rate of spread of all NL4-3 controls such that
RC values ,1.0 or .1.0 indicate rates of spread that were slower
than or faster than NL4-3, respectively. Each virus was assayed in
a minimum of two independent experiments and average RC
values are reported.
Assessment of HLA and CD4 downregulation capacity by
clonal Nef sequences
First-round Nef amplicons from 102 historic and 86 modern
patients were originally selected and amplified using second round
primers featuring EcoRI (forward) and SacII (reverse) restriction
sites. Amplicons were PCR-purified (GeneJET PCR Purfication
Kit, Thermo Scientific) and cloned into the pIRES2-EGFP
expression vector (Clontech) as described in [67,68]. For each
patient, a single representative clone harboring an intact Nef
reading frame that closely resembled the original bulk plasma HIV
RNA sequence by phylogenetic analysis was selected for functional
assessment.
CD4 and HLA class I downregulation activities for each Nef
clone were measured using a CEM-SS derived T cell line that
expresses high levels of surface CD4 and HLA-A*02 (CEM-A*02),
constructed as described in [107]. To assess Nef-mediated CD4
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5 CEM-A*02 cells were trans-
fected with 5 mg plasmid DNA encoding Nef protein and GFP by
electroporation (BioRad GenePulser MX). Twenty hours later,
cells were stained with APC-labeled anti-CD4 and PE-labeled
anti-HLA-A*02 antibodies (BD Biosciences) and cell surface
expression was measured in transfected (GFP-positive) cells by
flow cytometry (Guava easyCyte 8HT, Millipore). For patient-
derived Nef clones, the median fluorescence intensity (MFI) of
CD4 or HLA-A*02 expression in GFP-positive cells was normal-
ized to the MFI of CD4 or HLA-A*02 expression for the negative
control (empty pIRES2-EGFP plasmid) and positive control (nef
reference sequence SF2, cloned into pIRES2-EGFP) to determine
the relative CD4 or HLA-A*02 downregulation capacity. As such,
a normalized value of 0.0 indicates no downregulation activity and
a value of 1.0 indicates downregulation capacity equivalent to that
of the positive control NefSF2. All assays were performed in
triplicate and results are presented as the mean of these
measurements.
Steady state Nef protein levels were measured by Western blot
for the minority of Nef clones that displayed poor (,50%)
function for either CD4 or HLA-A*02 downregulation activity,
alongside 20 randomly-selected clones with activities above this
threshold. A total of 5610
6 CEM-A*02 cells were transfected by
electroporation with 10 mg of plasmid DNA, and cell pellets were
collected 20 hours later for preparation of total cell lysates, using
a protocol modified from [107]. Lysates were subjected to SDS-
PAGE in duplicate and electro-blotted onto PVDF membrane.
To ensure detection of patient-derived Nef, duplicate blots were
probed using anti-Nef polyclonal antisera developed from rabbit
(NIH AIDS Research and Reference Reagent Program Catalog
#2949, [108]) or sheep (ARP 444; NIBSC Center for AIDS
Reagents, UK). Actin expression was simultaneously assessed.
Band intensities were quantified on an ImageQuant LAS 4000
(GE Healthcare Life Sciences). A total of 15 poorly functional Nef
clones whose expression could not be detected by Western Blot
were excluded from analysis, as in vitro cloning or other defects
cannot be ruled out. This left 93 historic and 80 modern Nef
clones for analysis.
Supporting Information
Figure S1 HLA distribution in historic and modern cohorts.
HLA-A, B and C alleles with frequencies .0.01 in historic and
modern cohorts are shown. Alleles exhibiting significant frequency
differences between cohorts are indicated by ** (q,0.05,
corresponding to p,0.005) and * (q,0.2, corresponding to
p,0.05).
(EPS)
Figure S2 Nef phylogenetic trees incorporating historic, modern
and published HIV sequences from North America, colored by era
and site. Unrooted Maximum-Likelihood phylogenies constructed
from historic and modern Nef sequences are drawn on the same
distance scale, colored by era (Panel A) and site (Panel B). North
American HIV sequences retrieved from the Los Alamos (LANL)
database are in grey.
(EPS)
Figure S3 Gag and Nef Ancestral and Consensus amino acid
sequences. ‘‘ANCESTOR_NORTHAMERICA’’ is the recon-
structed ancestral amino acid sequence (same as blue sequence in
Figure 3). ‘‘HISTORIC_COHORT_CONS’’ is the consensus of
our historic cohort sequences. ‘‘LANL_CONSB_NORTHA-
MERICA’’ is the consensus of all Gag and Nef sequences
annotated with ‘‘Canada’’ or ‘‘USA’’ as their country of origin in
the Los Alamos HIV Database (see methods). ‘‘MODERN_CO-
HORT_CONS’’ is the consensus of our modern cohort
sequences. ‘‘LANL_CONSB_GLOBAL’’ is the most recent
(2004) HIV subtype B consensus sequence in the Los Alamos
HIV Database. (http://www.hiv.lanl.gov/content/sequence/
NEWALIGN/align.html)
(EPS)
Figure S4 Nef residues exhibiting significant diversification over
time are biased towards known HLA-associated sites. Panel A:
Differences in Shannon entropy (Dentropy) between modern and
historic sequences are shown for every Nef codon. Red bars
indicate significant (p,0.001, q,0.01) entropy differences; blue
bars indicate differences that are not significant (p$0.001). Grey
dots designate known HLA-associated sites. Green dots designate
sites that display significant evidence of pervasive positive selection
(dN/dS.1; posterior probability .0.9). Panel B: Same as panel
A, but sorted by decreasing magnitude of Dentropy. Panel C:
Graphical depiction of a 262 contingency table stratifying variable
(,99% conserved) Nef codons based on their status as HLA-
associated (yes vs. no), and whether they exhibited significant
Dentropy between modern and historic datasets (p,0.001 [red] vs.
not [blue]). Ns are indicated above each bar. Panel D: Graphical
depiction of a 262 contingency table stratifying variable (,99%
conserved) Nef codons based on their status as HLA-associated
(yes vs. no) and evidence that they are under significant pervasive
positive selection (dN/dS.1; posterior probability .0.9 [green]
vs. not [black]). Ns are indicated above each bar.
(EPS)
Figure S5 Differences in consensus escape mutant frequencies in
persons expressing versus lacking the restricting HLA allele(s), by
era. Panel A: The frequencies of published HLA-associated
polymorphisms, where the polymorphism represents the HIV
subtype B consensus residue [43] in historic (1979–1989) and
modern (2000+) HIV Gag sequences from individuals expressing
the restricting HLA allele(s) are shown as linked pairs. A selection
of well-known HLA-associated polymorphisms are labeled with
their codons and restricting allele(s). Panel B: Consensus
frequencies at these sites in historic and modern HIV Gag
sequences from individuals lacking the restricting HLA allele(s).
Panel C: Frequencies of published consensus HLA-associated
polymorphisms in HIV Nef sequences from historic and modern
individuals expressing the restricting HLA allele(s). Panel D:
Consensus frequencies at these sites in HIV Nef sequences from
historic and modern individuals lacking the restricting HLA
allele(s). All P-values were computed using the Wilcoxon
matched-pairs test.
(EPS)
Figure S6 Estimated ‘‘percentage of pre-adapted sites’’ in
historic versus modern circulating Gag and Nef sequences. The
overall burden of HIV polymorphisms that are ‘‘pre-adapted’’ to
an individuals’ full HLA class I profile (expressed in terms of %
‘‘pre-adapted’’ sites) for HIV sequences circulating in the historic
versus modern eras are shown, for Gag (Panel A) and Nef (Panel
B).
(EPS)
Figure S7 General positive correlation between the frequency of
an HLA allele and its associated HIV polymorphisms in the
population. Each dot illustrates a single HLA class I allele, colored
red, blue and green, for HLA-A, -B, and -C alleles, respectively. As
expected, a general positive correlation is observed between the
frequency of a given HLA allele in the population (y-axis) and the
frequency of its associated HIV polymorphisms in the population.
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(EPS)
Figure S8 Raw data from Gag and Nef functional assessments.
Panel A: In vitro replication capacities (RC) of recombinant NL4-3
viruses expressing inferred ancestral and global consensus B Gag
sequences, along with positive (NL4-3) and negative (cells only)
controls. RC of ancestral and consensus are equivalent to that of
NL4-3. Panel B: Representative flow cytometry plots depicting
the ability of the inferred ancestral Nef sequence to downregulate
CD4 from the cell surface, along with positive (Nef-SF2) and
negative (DNef) controls. CD4 downregulation capacity of the
inferred ancestral Nef sequences is comparable to that of control
strain SF2. Panel C: Representative flow cytometry plots
depicting the ability of the inferred ancestral Nef sequence to
downregulate HLA-A*02 from the cell surface, along with positive
(Nef SF2) and negative (DNef) controls. HLA-A*02 downregula-
tion capacity of the inferred ancestral Nef sequences is comparable
to that of control strain SF2. Panel D: Western Blots of SF2 Nef
(positive control), DNef (negative control), ancestral Nef, global
consensus B Nef, and representative patient-derived Nef clonal
sequences from modern and historic eras.
(EPS)
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